Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2014 2
2015 1
2017 2
2018 1
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ. Verstovsek S, et al. Among authors: garcia delgado r. Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901. Online ahead of print. Future Oncol. 2022. PMID: 36416118 Free article. Review.
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. Dawson MA, et al. Among authors: delgado rg. Clin Cancer Res. 2023 Feb 16;29(4):711-722. doi: 10.1158/1078-0432.CCR-22-1284. Clin Cancer Res. 2023. PMID: 36350312 Free PMC article. Clinical Trial.
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A, Gisslinger H, De Stefano V, Accurso V, Iurlo A, Devos T, Egyed M, Lippert E, Delgado RG, Cantoni N, Dahm AEA, Sotiropoulos D, Houtsma E, Smyth A, Iqbal A, Di Matteo P, Zuurman M, Te Boekhorst PAW. Theocharides A, et al. Among authors: delgado rg. Eur J Haematol. 2024 Mar;112(3):379-391. doi: 10.1111/ejh.14124. Epub 2023 Oct 30. Eur J Haematol. 2024. PMID: 37899734
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.
García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, García-Hernández MC, Gómez-Casares MT, Ferrer-Marín F, Saavedra S, Cervantes F, García-Delgado R, On Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin. García-Fortes M, et al. Among authors: garcia delgado r. Cancers (Basel). 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331. Cancers (Basel). 2022. PMID: 35565461 Free PMC article.
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F. Hernández-Boluda JC, et al. Among authors: garcia delgado r. Eur J Haematol. 2017 Apr;98(4):407-414. doi: 10.1111/ejh.12846. Epub 2017 Jan 19. Eur J Haematol. 2017. PMID: 28009442 Clinical Trial.
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Triguero A, Pedraza A, Pérez-Encinas M, Mata-Vázquez MI, Vélez P, Fox L, Gómez-Calafat M, García-Delgado R, Gasior M, Ferrer-Marín F, García-Gutiérrez V, Angona A, Gómez-Casares MT, Cuevas B, Martínez C, Pérez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernández-Boluda JC, Sanz C, Álvarez-Larrán A; On behalf of the MPN Spanish Group (GEMFIN). Triguero A, et al. Among authors: garcia delgado r. Ann Hematol. 2022 Oct;101(10):2231-2239. doi: 10.1007/s00277-022-04963-z. Epub 2022 Aug 30. Ann Hematol. 2022. PMID: 36042023 Free PMC article.
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Triguero A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, Vélez P, Fox L, Gomez-Calafat M, Garcia-Delgado R, Gasior M, Ferrer-Marin F, Garcia-Gutierrez V, Angona A, Gomez-Casares MT, Cuevas B, Martínez C, Pérez R, Raya JM, Guerrero L, Murillo I, Bellosillo B, Hernandez-Boluda JC, Sanz C, Alvarez-Larran A; On behalf of the MPN Spanish Group (GEMFIN). Triguero A, et al. Among authors: garcia delgado r. Ann Hematol. 2022 Dec;101(12):2819-2820. doi: 10.1007/s00277-022-05005-4. Ann Hematol. 2022. PMID: 36264368 Free PMC article. No abstract available.
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R, de Miguel D, Bailén A, González JR, Bargay J, Falantes JF, Andreu R, Ramos F, Tormo M, Brunet S, Figueredo A, Casaño J, Medina A, Badiella L, Jurado AF, Sanz G. García-Delgado R, et al. Leuk Res. 2014 Jul;38(7):744-50. doi: 10.1016/j.leukres.2014.03.004. Epub 2014 Mar 19. Leuk Res. 2014. PMID: 24795069 Free article.
14 results